Innate Pharma SA
Cyril Perrier is currently the R&D Team Manager for Immunoanalysis at Innate Pharma, a position held since May 2016, focusing on the development, optimization, qualification, and validation of binding ligand assays in accordance with FDA and EMA recommendations. Previous experience includes a role as a research assistant in the bioanalytical department at Virbac, where ELISA assays were developed and optimized, and an internship at IDEXX Laboratories that involved diagnostic tests for Enzootic Bovine Leukosis. Cyril has also interned at the Animal Health and Veterinary Laboratories Agency, focusing on Brucella, and at INSERM, studying macrophage behavior during bacterial infections. An academic background includes a Master's degree in Biotin management from the University of Montpellier and a Bachelor's degree in Biology Health from Université de Nîmes. Key competencies encompass in vivo experimentation, qRT-PCR, and microscopy techniques.
This person is not in any teams
This person is not in any offices
Innate Pharma SA
2 followers
Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The Company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.